Details of the Drug
General Information of Drug (ID: DMZWAQ3)
| Drug Name |
DXL-625
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
DXLr-120; Anti-CD20 monoclonal antibodies (DXL, cancer), InNexus; Autophilic peptide conjuagted rituximab (rheumatoid arthritis/NHL/CLL), InNexus; Anti-CD20 monoclonal antibodies (DXL, non-Hodgkin's lymphoma/ rheumatoid arthritis), InNexus
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||

